ADVANZ PHARMA SERVICES (UK) LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ADVANZ PHARMA SERVICES (UK) LIMITED 2018-10-30 → present
2. CONCORDIA INTERNATIONAL RX (UK) LIMITED 2016-06-17 → 2018-10-30
3. AMDIPHARM MERCURY COMPANY LIMITED 2013-03-22 → 2016-06-17
4. MERCURY PHARMA MANAGEMENT SERVICES LIMITED 2012-03-20 → 2013-03-22
5. GOLDSHIELD MANAGEMENT SERVICES LTD 2003-02-26 → 2012-03-20

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Grant Thornton

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realise its assets and discharge its liabilities in the normal course of operations as they fall due. In assessing the ability of the Company to continue as a going concern, the directors have taken account of the loss in 2025 of £154, the cumulative profits of £22,950, and the Company's net current assets and net asset position of £52,634 and £54,128, respectively at 31 December 2025. The Company's Intermediate Holding Company, APHL has provided the Company with a letter of support indicating its intention to provide financial support required for a period of at least 12 months from the date these financial statements are approved. After making enquiries, considering the Group's forecasts and projections and considering the letter of support received from APHL, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the directors consider it appropriate to prepare these entity financial statements on a going concern basis.”

Significant events

• “On 15 July 2021, the CMA issued a decision that it considered that competition infringements had occurred, including by certain ADVANZ PHARMA affiliates... The Company and the Group did not believe that it had infringed competition law and appealed the decision.”
• “On 26 July 2024, NHS Scotland commenced protective litigation at the CAT against most of the Hydrocortisone appellants for all of the allegations... Given the inability to reliably estimate or measure the potential liability... the Company and the Group has not recorded any provision as of 31 December 2025.”
• “On 8 May 2025, the Court of Appeal upheld the CMA's decision regarding the infringement of competition law. The Company and the Group then filed permission to appeal with the Supreme Court, which was subsequently declined; no further appeals are possible.”
• “There were no subsequent events affecting the company's operations since the balance sheet date.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.